Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail

Giannakouros,Panagiota; Matte,Isabelle; Rancourt,Claudine; Piché,Alain

doi:10.3892/ijo.2014.2707

Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail

Authors:
- Panagiota Giannakouros
- Isabelle Matte
- Claudine Rancourt
- Alain Piché
View Affiliations

Affiliations: Département de Microbiologie et Infectiologie, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada
Published online on: October 14, 2014 https://doi.org/10.3892/ijo.2014.2707
Pages: 91-98

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MUC16 (CA125) is a transmembrane mucin that contributes to the progression of epithelial ovarian cancer (EOC). Expression of MUC16 is not detectable in the epithelial surface of normal ovaries. MUC16 expression is, however, common in serous EOC as well as in metastatic and recurrent tumors. Despite these observations, its contribution to the development of EOC is unknown. We stably expressed either empty vector, MUC16 C-terminal domain (MUC16 CTD) or MUC16 TMU (a construct that lacks the cytoplasmic tail) in NIH3T3 mouse fibroblast cells. In this study, we provide evidence for the role of MUC16 CTD in oncogenic transformation. We show that ectopic expression of MUC16 CTD enhances the growth of NIH3T3 cells under normal and low serum conditions, and promotes anchorage-dependent colony formation. The deletion of the cytoplasmic tail abrogated these effects. MUC16 CTD expression in NIH3T3 cells also enhances the formation of colony in soft agar as compared to MUC16 TMU. MUC16 CTD expression enhances tumor formation in nude mice. Our findings provide the first evidence that MUC16 induces the transformation of NIH3T3 cells and indicate that MUC16 functions as an oncogene. Furthermore, our data suggest that the cytoplasmic tail is critical for MUC16 oncogenic properties.

View Figures

View References

1	Auersperg N, Wong AS, Choi KC, et al: Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev. 22:255–288. 2001.PubMed/NCBI
2	Bast RC Jr, Feeney M, Lazarus H, et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 68:1331–1337. 1981. View Article : Google Scholar : PubMed/NCBI
3	Canney PA, Moore M, Wilkinson PM, et al: Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 50:765–769. 1984. View Article : Google Scholar : PubMed/NCBI
4	Kabawat SE, Bast RC, Welch WR, et al: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol. 79:98–104. 1983.
5	Nap M, Vitali A, Nustad K, Bast RC Jr, O’Brien TJ, et al: Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumor Biol. 17:325–331. 1996. View Article : Google Scholar : PubMed/NCBI
6	Nustad K, Bast RC Jr, O’Brien TJ, et al: Specificity and affinity of 26 monoclonal antibodies against the CA125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumor Biol. 17:196–219. 1996. View Article : Google Scholar
7	Høgdall EV, Christensen L, Kjaer SK, et al: CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients: from the Danish MALOVA ovarian cancer study. Gynecol Oncol. 104:508–515. 2007.
8	Ong A, Maines-Bandiera SL, Roskelley CD and Auersperg N: An ovarian adenocarcinoma line derived from SV40/E-cadherin-transfected normal human ovarian surface epithelium. Int J Cancer. 85:430–437. 2000. View Article : Google Scholar : PubMed/NCBI
9	Zheng J, Mercado-Uribe I, Rosen DG, et al: Induction of papillary carcinoma in ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle. 9:140–146. 2010. View Article : Google Scholar
10	Bast RC Jr, Klug TL, St John E, et al: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng J Med. 309:883–887. 1983. View Article : Google Scholar : PubMed/NCBI
11	Vergote IB, Børmer OP and Abeler VM: Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 157:88–92. 1987. View Article : Google Scholar : PubMed/NCBI
12	Bafna S, Kaur S and Batra SK: Membrane-bound mucins: the mechanistic basis for alteration of the growth and survival of cancer cells. Oncogene. 29:2893–2904. 2010. View Article : Google Scholar : PubMed/NCBI
13	Yin BW and Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin (Muc16). J Biol Chem. 276:27371–27375. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yin BW, Dnistrian A and Lloyd KO: Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer. 98:737–740. 2002. View Article : Google Scholar : PubMed/NCBI
15	O’Brien TJ, Beard JB, Underwood LJ, et al: The CA125 gene: an extracellular superstructure dominated by repeated sequences. Tumour Biol. 22:348–366. 2001.PubMed/NCBI
16	O’Brien TJ, Beard JB, Underwood LJ and Shigemasa K: The CA125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol. 23:154–169. 2002.PubMed/NCBI
17	de los Frailes MT, Stark S, Jaeger W, et al: Purification and characterization of the CA 125 tumor-associated antigen from human ascites. Tumor Biol. 14:18–29. 1993.PubMed/NCBI
18	Kobayashi H, Ida W, Terao T and Kawashima Y: Molecular characteristics of the CA 125 antigen produced by human endometrial epithelial cells: comparison between eutopic and heterotopic epithelial cells. Am J Obstet Gynecol. 169:725–730. 1993. View Article : Google Scholar
19	Fendrick JL, Staley KA, Gee MK, et al: Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line. Tumor Biol. 14:310–318. 1993. View Article : Google Scholar : PubMed/NCBI
20	Nagata A, Hirota N, Sakai T, et al: Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen. Tumor Biol. 12:279–286. 1991. View Article : Google Scholar : PubMed/NCBI
21	Fendrick JL, Konishi I, Geary SM, et al: CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumor Biol. 18:278–289. 1997. View Article : Google Scholar : PubMed/NCBI
22	Seelenmeyer C, Wegehingel S, Lechner J and Nickel W: The cancer antigen CA125 represents a novel counter receptor for galectin-1. J Cell Sci. 116:1305–1318. 2003. View Article : Google Scholar : PubMed/NCBI
23	Perillo NL, Marcus ME and Baum LG: Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med. 76:402–412. 1998. View Article : Google Scholar : PubMed/NCBI
24	Rump A, Morikawa Y, Tanaka M, et al: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 279:190–198. 2004. View Article : Google Scholar : PubMed/NCBI
25	Gubbels JA, Belisle J, Onda M, et al: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 5:502006. View Article : Google Scholar : PubMed/NCBI
26	Patankar MS, Jing Y, Morrison JC, et al: Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol. 99:704–713. 2005. View Article : Google Scholar : PubMed/NCBI
27	Gubbels JA, Felder M, Horibata S, et al: MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 9:112010. View Article : Google Scholar : PubMed/NCBI
28	Belisle JA, Gubbels JA, Raphael CA, et al: Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunol. 122:418–429. 2007. View Article : Google Scholar : PubMed/NCBI
29	Belisle JA, Horibata S, Jennifer GA, et al: Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 9:1182010. View Article : Google Scholar : PubMed/NCBI
30	Boivin M, Lane D, Piché A and Rancourt C: CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol. 115:407–413. 2009. View Article : Google Scholar : PubMed/NCBI
31	Matte I, Lane D, Boivin M, et al: MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer. 14:2342014. View Article : Google Scholar : PubMed/NCBI
32	Thériault C, Pinard M, Comamala M, et al: MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 121:434–443. 2011.PubMed/NCBI
33	Piché A, Grim J, Rancourt C, et al: Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58:2134–2140. 1998.PubMed/NCBI
34	Kasono K, Heike Y, Xiang J, et al: Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562. Cancer Gene Ther. 7:151–159. 2000. View Article : Google Scholar : PubMed/NCBI
35	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
36	Zietarska M, Maugard CM, Filali-Mouhim A, et al: Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog. 46:872–885. 2007. View Article : Google Scholar : PubMed/NCBI
37	Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar
38	Bedrosian I, Lu KH, Verschraegen C and Keyomarsi K: Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 23:2648–2657. 2004. View Article : Google Scholar : PubMed/NCBI
39	Comamala M, Pinard M, Thériault C, et al: Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signaling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer. 104:989–999. 2011. View Article : Google Scholar : PubMed/NCBI
40	Li Y, Liu D, Chen D, et al: Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 22:6107–6110. 2003. View Article : Google Scholar : PubMed/NCBI
41	Bafna S, Singh AP, Moniaux N, et al: MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells. Cancer Res. 68:9231–9238. 2008. View Article : Google Scholar
42	Satoh S, Hinoda Y, Hayashi T, et al: Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer. 88:507–518. 2000. View Article : Google Scholar : PubMed/NCBI
43	Singh AP, Moniaux N, Chauhan SC, et al: Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 64:622–630. 2004. View Article : Google Scholar : PubMed/NCBI
44	Komatsu M, Jepson S, Arango ME, et al: Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene. 20:461–470. 2001. View Article : Google Scholar : PubMed/NCBI
45	Sasaki R, Narisawa-Saito M, Yugawa T, et al: Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis. 30:423–431. 2009. View Article : Google Scholar : PubMed/NCBI
46	Mullany LK, Fan HY, Liu Z, et al: Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene. 30:3522–3536. 2011. View Article : Google Scholar : PubMed/NCBI